Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
Primary Purpose
Hip Fractures, Osteoporotic Fractures, Osteoporosis
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
hip Xray
Sponsored by
About this trial
This is an interventional prevention trial for Hip Fractures
Eligibility Criteria
Inclusion Criteria:
- Adults over 18 years old
- Patients diagnosed with low energy osteoporotic hip fracture, and was treated under surgery.
Exclusion Criteria:
- Patients not diagnosed with osteoporosis.
- Patients diagnosed with high energy osteoporotic hip fracture.
- Patients that suffered from Multiple Trauma.
- Patients diagnosed with Metabolic diseases or Genetic diseases.
- Pregnant women
Sites / Locations
- Meir Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
osteoporotic hip fracture
Arm Description
Outcomes
Primary Outcome Measures
Reduce number of incidents of secondary hip fracture.
Secondary Outcome Measures
Full Information
NCT ID
NCT02223572
First Posted
August 21, 2014
Last Updated
August 21, 2014
Sponsor
pninarotman
Collaborators
Meir Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02223572
Brief Title
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
Official Title
Secondary Fracture Prevention in Patients Hospitalized for Hip Fracture: Adding the Metabolic Treatment to the Surgical One.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2014
Overall Recruitment Status
Unknown status
Study Start Date
September 2014 (undefined)
Primary Completion Date
April 2016 (Anticipated)
Study Completion Date
May 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
pninarotman
Collaborators
Meir Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Due to its prevalence worldwide, osteoporosis is considered a serious public health concern. The worldwide annual incidence of Osteoporotic fractures is approximately 2 million in the US only.
Hip fracture is associated with serious disability and excess mortality. Studies have shown that an initial osteoporotic fracture is a major risk factor for a new fracture. An increased risk of 14.8% for a secondary hip fracture has been demonstrated in people that have already sustained a fracture in the past 4 years (In average). These data indicate the major opportunity afforded by secondary fracture prevention strategies.
By responding to the first fracture, we can reduce the incidence of second and subsequent fractures. However, even after longer medical follow-up according to regular standard of care, medical treatment and rehabilitation, the medical system has been unable to translate the eminent risk into an effective preventive treatment.
Detailed Description
Study Objectives:
To create a treatment, follow up and rehabilitation protocol for patients who suffered from a hip fracture, in order to prevent a secondary fracture.
To demonstrate that a combined treatment from the Hip Fractures Clinic as well as the regular standard treatment and rehabilitation suggested by the Bone Health Clinic (both in addition to standard medication prescribed for osteoporosis) will result in a significant reduction of second and subsequent fractures.
Study Protocol:
The study protocol will begin after the patients, who have been admitted with a primary hip fracture (of osteoporotic nature), were surgically treated (as customary standard of care).
According to hospitalization standard protocol, the patients will be treated with vitamin D and calcium. For the first month the patient will be given a loading dose of 70,000 units. For the next months the patients will receive 50,000-80,000 units per month.
In addition, the patient will be treated with Calcium Pills (Caltrate TAB 600mg, once a day)
In addition to the clinical customary monitoring tests performed during the hospitalization, Biomarkers and safety assessment will be taken:
Vitamin D
Bone Markers - Bone markers will be taken three days after the patient was admitted, and one more time six months later (as part of follow up visit).
Follow up visits after hospitalization due to surgery for primary hip fracture.
Follow up visits at the Hip Fracture Clinic will occur in intervals of: six weeks, 3 months, 6 months and a year, since the patient had been released from hospitalization. At follow up visit, the patient will be assessed for physical examination, hip X-ray and the rehabilitation progression Questionnaire (HHS).
Follow up visits at the Bone Health Clinic will occur between 6 weeks to 3 months since the patient had been released from hospitalization (as part of regular standard of care).
A 3cc Serum sample will be taken with the purpose to serve on future studies and examine new markers such as bone markers SCLEROSTIN. There will be no further use of these samples. The samples will remain in deep freeze temperature (C˚70-).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hip Fractures, Osteoporotic Fractures, Osteoporosis
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
osteoporotic hip fracture
Arm Type
Experimental
Intervention Type
Radiation
Intervention Name(s)
hip Xray
Primary Outcome Measure Information:
Title
Reduce number of incidents of secondary hip fracture.
Time Frame
1 year and 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults over 18 years old
Patients diagnosed with low energy osteoporotic hip fracture, and was treated under surgery.
Exclusion Criteria:
Patients not diagnosed with osteoporosis.
Patients diagnosed with high energy osteoporotic hip fracture.
Patients that suffered from Multiple Trauma.
Patients diagnosed with Metabolic diseases or Genetic diseases.
Pregnant women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pnina Rotman, MD
Phone
+972-9-7472671
Email
Pnina.Rotman@clalit.org.il
First Name & Middle Initial & Last Name or Official Title & Degree
Eyal Yaacobi, MD
Phone
+972-3-9385700
Email
Eyal.Yaacobi@clalit.org.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eyal Yaacobi, M.D.
Organizational Affiliation
Meir Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Pnina Rotman, MD
Organizational Affiliation
Meir Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Meir Medical Center
City
Kfar-Saba
ZIP/Postal Code
44281
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eyal Yaacobi, MD
Phone
972-3-9385700
Email
Eyal.Yaacobi@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Pnina Rotman, MD
Phone
972-9-7472671
Email
Pnina.Rotman@clalit.org.il
12. IPD Sharing Statement
Learn more about this trial
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
We'll reach out to this number within 24 hrs